E. Mamessier, K. Botturi, D. Vervloet, and A. Magnan, [T regulatory lymphocytes, atopy and asthma: a new concept in three dimensions]. Rev Mal Respir, pp.305-316, 2005.

D. Blic, J. Deschildre, A. Pin, I. Dubus, J. et al., When and how to modify the management of asthma in children over the age of 4], Rev Mal Respir, 2009.

P. Guide, A. Management, |. Prevention, /. Documents, |. Resources et al., Available from: http://www.ginasthma.org/documents/1/Pocket-Guide-for-Asthma-Management-and- Prevention, 2015.

G. Report, Global Strategy for Asthma Management and Prevention | Documents

A. Stelmaszczyk-emmel, Regulatory T cells in children with allergy and asthma: It is time to act, Respiratory Physiology & Neurobiology, vol.209, 2014.
DOI : 10.1016/j.resp.2014.11.010

D. Hartl, B. Koller, A. Mehlhorn, D. Reinhardt, T. Nicolai et al., Quantitative and functional impairment of pulmonary CD4+CD25hi regulatory T cells in??pediatric asthma, Journal of Allergy and Clinical Immunology, vol.119, issue.5, pp.1258-66, 2007.
DOI : 10.1016/j.jaci.2007.02.023

M. Yüksek, F. Erol, D. Gülo?lu, F. Do?u, A. Elhan et al., Regulatory T cell levels in children with asthma, Turk J Pediatr, vol.53, issue.5, pp.532-538, 2011.

S. Provoost, T. Maes, Y. Van-durme, P. Gevaert, C. Bachert et al., Decreased FOXP3 protein expression in patients with asthma, Allergy, vol.132, issue.10, 2009.
DOI : 10.1111/j.1398-9995.2009.02056.x

C. Karagiannidis, M. Akdis, P. Holopainen, N. Woolley, G. Hense et al., Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma, Journal of Allergy and Clinical Immunology, vol.114, issue.6, pp.1425-1458, 2004.
DOI : 10.1016/j.jaci.2004.07.014

J. Bousquet, K. Rabe, M. Humbert, K. Chung, W. Berger et al., Predicting and evaluating response to omalizumab in patients with severe allergic asthma, Respiratory Medicine, vol.101, issue.7, pp.1483-92, 2007.
DOI : 10.1016/j.rmed.2007.01.011

N. Hanania, S. Wenzel, K. Rosén, H. Hsieh, S. Mosesova et al., Exploring the Effects of Omalizumab in Allergic Asthma, American Journal of Respiratory and Critical Care Medicine, vol.187, issue.8, pp.804-815, 2013.
DOI : 10.1164/rccm.201208-1414OC

P. Chanez, C. Contin-bordes, G. Garcia, C. Verkindre, A. Didier et al., Omalizumab-induced decrease of Fc??RI expression in patients with severe allergic asthma, Respiratory Medicine, vol.104, issue.11, pp.1608-1625, 2010.
DOI : 10.1016/j.rmed.2010.07.011

F. Urbano, EPR-3) on Asthma Diagnosis and Treatment Guidelines, Expert Panel Report J Manag Care Pharm JMCP Feb, vol.14, issue.1, pp.41-50, 2007.

N. Beydon, S. Davis, E. Lombardi, J. Allen, H. Arets et al., An Official American Thoracic Society/European Respiratory Society Statement: Pulmonary Function Testing in Preschool Children, American Journal of Respiratory and Critical Care Medicine, vol.175, issue.12, pp.1304-1349, 2007.
DOI : 10.1164/rccm.200605-642ST

M. Asher, U. Keil, H. Anderson, R. Beasley, J. Crane et al., International study of asthma and allergies in childhood (ISAAC): rationale and methods, European Respiratory Journal, vol.8, issue.3, pp.483-91, 1995.
DOI : 10.1183/09031936.95.08030483

I. Annesi-maesano, A. Didier, M. Klossek, I. Chanal, D. Moreau et al., The score for allergic rhinitis (SFAR): a simple and valid assessment method in population studies, Allergy, vol.57, issue.2, pp.107-121, 2002.
DOI : 10.1034/j.1398-9995.2002.1o3170.x

URL : https://hal.archives-ouvertes.fr/hal-00595555

D. Maselli, H. Singh, J. Diaz, and J. Peters, Efficacy of omalizumab in asthmatic patients with IgE levels above 700 IU/mL: a retrospective study Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol, pp.457-61, 2013.

L. Grimaldi-bensouda, M. Zureik, M. Aubier, M. Humbert, J. Levy et al., Does Omalizumab Make a Difference to the Real-life Treatment of Asthma Exacerbations?, Chest, vol.143, issue.2, pp.398-405
DOI : 10.1378/chest.12-1372

G. Braunstahl, C. Chen, R. Maykut, P. Georgiou, G. Peachey et al., The eXpeRience registry: The ???real-world??? effectiveness of omalizumab in allergic asthma, Respiratory Medicine, vol.107, issue.8, pp.1141-51, 2013.
DOI : 10.1016/j.rmed.2013.04.017

N. Barnes, A. Menzies-gow, A. Mansur, D. Spencer, F. Percival et al., Effectiveness of Omalizumab in Severe Allergic Asthma: A Retrospective UK Real-World Study, Journal of Asthma, vol.91, issue.53, pp.529-565
DOI : 10.1016/j.rmed.2010.04.013

W. Busse, S. Spector, K. Rosén, Y. Wang, and O. Alpan, High eosinophil count: A potential biomarker for assessing successful omalizumab treatment effects, Journal of Allergy and Clinical Immunology, vol.132, issue.2, pp.485-491, 2013.
DOI : 10.1016/j.jaci.2013.02.032

R. Djukanovi?, S. Wilson, M. Kraft, N. Jarjour, M. Steel et al., Effects of Treatment with Anti-immunoglobulin E Antibody Omalizumab on Airway Inflammation in Allergic Asthma, American Journal of Respiratory and Critical Care Medicine, vol.170, issue.6, pp.583-93, 2004.
DOI : 10.1164/rccm.200312-1651OC

M. Massanari, S. Holgate, W. Busse, P. Jimenez, F. Kianifard et al., Effect of omalizumab on peripheral blood eosinophilia in allergic asthma, Respiratory Medicine, vol.104, issue.2, 2010.
DOI : 10.1016/j.rmed.2009.09.011

L. Boulet and P. Chanez, Clinically relevant outcome measures for new therapies of asthma using pharmaceutical and biologic agents, Current Opinion in Allergy and Clinical Immunology, vol.15, issue.3, 2015.
DOI : 10.1097/ACI.0000000000000165

A. Ray, A. Khare, N. Krishnamoorthy, Z. Qi, and P. Ray, Regulatory T cells in many flavors control asthma, Mucosal Immunology, vol.174, issue.3, pp.216-245, 2010.
DOI : 10.1126/science.7520605